- Home
- CPRX vs WVE Comparison
CPRX vs WVE Comparison
Compare CPRX & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- WVE
- Stock Information
- Founded
- CPRX 2002
- WVE 2012
- Country
- CPRX United States
- WVE Singapore
- Employees
- CPRX N/A
- WVE N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- WVE Health Care
- Exchange
- CPRX Nasdaq
- WVE Nasdaq
- Market Cap
- CPRX 2.8B
- WVE 2.4B
- IPO Year
- CPRX 2006
- WVE 2015
- Fundamental
- Price
- CPRX $20.60
- WVE $13.67
- Analyst Decision
- CPRX Strong Buy
- WVE Strong Buy
- Analyst Count
- CPRX 6
- WVE 10
- Target Price
- CPRX $30.50
- WVE $21.30
- AVG Volume (30 Days)
- CPRX 984.3K
- WVE 1.3M
- Earning Date
- CPRX 11-06-2024
- WVE 11-12-2024
- Dividend Yield
- CPRX N/A
- WVE N/A
- EPS Growth
- CPRX 114.68
- WVE N/A
- EPS
- CPRX 1.18
- WVE N/A
- Revenue
- CPRX $460,482,000.00
- WVE $53,610,000.00
- Revenue This Year
- CPRX $21.99
- WVE N/A
- Revenue Next Year
- CPRX $17.95
- WVE N/A
- P/E Ratio
- CPRX $17.48
- WVE N/A
- Revenue Growth
- CPRX 32.17
- WVE N/A
- 52 Week Low
- CPRX $13.00
- WVE $3.50
- 52 Week High
- CPRX $24.27
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- CPRX 39.71
- WVE 50.96
- Support Level
- CPRX $21.30
- WVE $14.95
- Resistance Level
- CPRX $24.27
- WVE $16.71
- Average True Range (ATR)
- CPRX 0.79
- WVE 1.04
- MACD
- CPRX -0.18
- WVE -0.28
- Stochastic Oscillator
- CPRX 4.18
- WVE 14.72
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.